At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Presatovir +1 moredrug
Likely dose
Presatovir 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
In Brief
A Phase 2 clinical trial evaluating Presatovir and Placebo for Respiratory Syncytial Virus Infection. Completed, enrolled 60 participants across 17 sites in 5 countries.
Detailed Summary
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus Infection
CountriesFrance, South Korea, Sweden, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJan 2015
Primary CompletionApr 2017
TodayJul 2026
First PostedOct 1, 2014
Enrollment StartJan 31, 2015
Primary CompletionApr 17, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.8 years ago
Interventions
Presatovirdrug
Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
Placebodrug
Placebo to match presatovir administered orally or via nasogastric tube